跳至主要内容
临床试验/CTRI/2024/02/063257
CTRI/2024/02/063257尚未招募不适用

Clinical Evaluation of irritation potential of Hair Care formulation on healthy human subjects

Dabur International Limited1 个研究点 分布在 1 个国家目标入组 26 人开始时间: 2024年3月3日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
尚未招募
入组人数
26
试验地点
1
主要终点
Dermatological safety / Irritation potential on skin

研究概览

简要总结

Objective: The objective of this clinical study will be to evaluate the irritation potential on healthy human subjects of Hair Care Formulations.

 Duration of study: 8 days study

 Kinetics: T-2 day(sensitivity test), T0 (Evaluation of test sites by Dermatologist, Patch application) ,T1(Patch removal, Evaluation of test sites by Dermatologist ,T2(Evaluation of test sites by Dermatologist and Subject post 24 hrs of patch removal), T8 (Evaluation of test sites by Dermat and Subject post 1 week of patch removal and tracking the positive cases)

 Population: 26 healthy subjects (13 males + 13 females).

 The test area is checked for erythema and oedema caused due to the product and compared with positive control

研究设计

研究类型
Interventional
分配方式
Na
盲法
None

入排标准

年龄范围
18.00 Year(s) 至 65.00 Year(s)(—)
性别
All

入选标准

  • •Asian Indian male and female subjects 2) Healthy human subjects (no infectious and evolutive pathology which could make the subject vulnerable and stop the study, no pathology which could interfere with the study, no symptom in the process of an exploratory check-up) 3) Between 18 and 65 years of age 4) Skin is healthy on the studied anatomic unit (free of eczema,wounds, inflammatory scar….) 5)subjects who show no allergic / irritation symptoms to the test product at skin sensitivity test will be enrolled in the study.

排除标准

  • •1 For female: Being pregnant or breastfeeding or having stopped to breastfeed in the past three months 2 Having refused to give his/her assent by not signing the consent form 3 Taking part in another study liable to interfere with this study 4 Being diabetic.
  • •5 Being asthmatic.
  • •6 Following a chronic medicinal treatment comprising any of the following products: aspirin-based products, anti-inflammatories, antihistamines, corticotherapy, taken by general or local routes (the only medication permitted is paracetamol).
  • •7 Having cutaneous hypersensitivity (except in the case of studies with evaluation of sensitive skin).
  • •8 Having a diagnosed or highly probable allergy to one or several compounds of the cosmetic products.
  • •9 Having undergone a surgery requiring a general anaesthesia of more than one hour in the past 6 months.

结局指标

主要结局

Dermatological safety / Irritation potential on skin

时间窗: Baseline,0 hrs,24 hrs and 7 days

次要结局

未报告次要终点

研究者

申办方类型
Other [fmcg]
责任方
Principal Investigator
主要研究者

Dr Raji Patil

MASCOT-SPINCONTROL India Pvt. Ltd.

研究点 (1)

Loading locations...

相似试验